Femoral Artery StenosisLEVANT 2NCT01412541
Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Femoropopliteal Arteries
A study testing Standard Uncoated Angioplasty Balloon and Moxy Drug Coated Balloon in people with Femoral Artery Stenosis and Popliteal Artery Stenosis, run by C. R. Bard at 54 sites in 4 countries.
Trial summary
The purpose of the study is to demonstrate the superior efficacy and non-inferior safety of the Moxy Drug Coated Balloon by direct comparison to standard percutaneous transluminal angioplasty (PTA) catheter for treatment of stenosis of the femoropopliteal arteries. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion
- What is being tested?
- Standard Uncoated Angioplasty Balloon and Moxy Drug Coated Balloon
- Type of treatment
- Medical device, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 532 participants
- Where
- 54 sitesin 4 countries
- Study dates
- Jul 2011to Dec 2018
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Patients will be excluded if ANY of the following conditions apply:
- Pregnant or planning on becoming pregnant or men intending to father children;
- Life expectancy of <5 years;
- Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed.
- History of hemorrhagic stroke within 3 months;
- Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure;
Show all 19Show fewer
- History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of enrollment;
- Rutherford Class 0, 1, 5 or 6;
- Renal failure or chronic kidney disease with modification in diet in renal disease glomerular filtration rate (MDRD GFR) ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis);
- Prior vascular surgery of the index limb, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;
- Inability to take required study medications or allergy to contrast that cannot be adequately managed with pre- and post-procedure medication;
- Anticipated use of IIb/IIIa inhibitor prior to randomization;
- Ipsilateral retrograde access;
- Composite lesion length is >15 cm or there is no normal proximal arterial segment in which duplex flow velocity can be measured;
- Significant inflow disease. Successful treatment of inflow disease allowed prior to target lesion treatment;
- Known inadequate distal outflow (>50 % stenosis of distal popliteal and/or all three tibial vessels), or planned future treatment of vascular disease distal to the target lesion;
- Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel;
- Severe calcification that renders the lesion un-dilatable;
- Use of adjunctive treatment modalities (i.e. laser, atherectomy, cryoplasty, scoring/cutting balloon, etc.).
Trial locations and contacts
54 sites in 4 countries.
54 sites in 4 countries
United States42 sites
Austin Heart P.A.
Austin, Texas, 78705
Massachusetts Genearl Hospital
Boston, Massachusetts, 02114
Deborah Heart and Lung Center
Browns Mills, New Jersey, 08015
Our Lady of Lourdes Medical Center
Cherry Hill, New Jersey, 08034
Christ Hospital / The Lindner Clinical Trial Center
Cincinnati, Ohio, 45219
Heart and Vascular Institute
Clearwater, Florida, 33756
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
Cleveland Clinic
Cleveland, Ohio, 44195
Mid Ohio Cardiology and Vascular Consultants
Columbus, Ohio, 43214
Mercy Hosptial
Coon Rapids, Minnesota, 55433
Methodist Medical Center
Des Moines, Iowa, 50309
Detroit Medical Center
Detroit, Michigan, 48201
St. John's Hospital
Detroit, Michigan, 48236
Cardiovascular Associates
Elk Grove Village, Illinois, 60007
Allen County Cardiology
Fort Wayne, Indiana, 46802
Interventional Cardiolgists of Gainesville
Gainesville, Florida, 32605
Greenville Memorial Hospital
Greenville, South Carolina, 29615
Forrest General Hospital
Hattiesburg, Mississippi, 39401
Promise Regional Medical Center
Hutchinson, Kansas, 67502
St. Vincent Heart Center of Indianapolis
Indianapolis, Indiana, 46260
Wellmont Cardiology Services
Kingsport, Tennessee, 37660
East Tennessee Heart Consultants
Knoxville, Tennessee, 37934
Good Samaritan Hospital
Los Angeles, California, 90017
Medical Center of the Rockies
Loveland, Colorado, 80538
Baptist DeSoto in Southaven
Memphis, Tennessee, 38120
Yale New Haven Hospital
New Haven, Connecticut, 06510
New York University Medical Center
New York, New York, 10010
Mount Sinai Medical Center
New York, New York, 10029
Columbia Universtiy Medical Center
New York, New York, 10032
Advocate Christ Medical Center
Oak Lawn, Illinois, 60453
Edward Heart
Oakbrook Terrace, Illinois, 60181
Munroe Regional Medical Center
Ocala, Florida, 34471
North County Radiology Medial Group Inc.
Oceanside, California, 92056
St. Joseph's Hospital
Orange, California, 92868
Wake Heart and Vascular
Raleigh, North Carolina, 27610
University of California Davis
Sacramento, California, 95817
St. John's Hospital
Springfield, Illinois, 62701
Jobst Vascular Institute
Toledo, Ohio, 43606
Univesrity of Toledo Medical Center
Toledo, Ohio, 43614
St. Francis Heart & Vascular Center
Topeka, Kansas, 66606
Washington Cardiology Center
Washington D.C., District of Columbia, 20010
Michigan Heart
Ypsilanti, Michigan, 48197
Germany8 sites
Herz-Zentrum
Bad Krozingen, 79189
Jewish Hospital
Berlin, 13347
Universitätsklinikum Carl Gustav Carus
Dresden, 01307
Diakonissenanstalt zu Flensburg
Flensburg, 24939
Hamburg University Cardiovascular Center
Hamburg, 22527
University Leipzig
Leipzig, 04103
University Magdeburg
Magdeburg, 39120
University of Tübingen
Tübingen, 72076
Austria2 sites
Medical University of Graz
Graz, A-8036
Medical University of Vienna
Vienna, 1090
Belgium2 sites
Imelda Ziekenhuis
Bonheiden, 2820
Flanders Medical Research Program
Dendermonde, 9200
About this study
Official title: A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries
The purpose of the study is to demonstrate the superior efficacy and non-inferior safety of the Moxy Drug Coated Balloon by direct comparison to standard percutaneous transluminal angioplasty (PTA) catheter for treatment of stenosis of the femoropopliteal arteries.
Read the detailed description
The Moxy Drug Coated Balloon is indicated for percutaneous transluminal angioplasty of obstructive de novo or non-stented restenotic lesions in native femoropopliteal arteries up to 15 cm in length and ≥4.0 to ≤6.0 mm in diameter. This study will randomize approximately 476 patients who will receive either the Moxy balloon or standard balloon angioplasty at 55 global investigational sites. Subjects will be blinded to treatment until 12 months and will participate in long term follow-up for 5 years.
- Conditions
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
- Being tested
- Standard Uncoated Angioplasty Balloon, Moxy Drug Coated Balloon
- Keywords
- Arms, Experimental, Drug Coated Angioplasty Balloon, Active Comparator, Standard Angioplasty Balloon
- Medical subject headings
- Rhabdomyosarcoma, Alveolar
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Standard Uncoated Angioplasty BalloonProcedure or surgery
Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
Moxy Drug Coated BalloonDevice
Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
| Study group | Role | What they receive |
|---|---|---|
| Moxy Drug Coated Balloon | Experimental | Paclitaxel coated balloon catheter Receives: Device: Moxy Drug Coated Balloon |
| Standard Uncoated Angioplasty Balloon | Active comparator | PTA Catheter Receives: Procedure: Standard Uncoated Angioplasty Balloon |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Composite Freedom From All-Cause Peri-Operative (≤30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 12 Months Post Index Procedure
Composite of freedom from all-cause peri-operative (≤30 day) death and freedom at 1 year from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.
Measured: 12 months post index procedure
Percentage of Participants With Primary Patency of the Target Lesion at 12 Months Post Index Procedure
Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) ≥2.5) and freedom from target lesion revascularization (TLR).
Measured: 12 months post index procedure
Secondary outcomes (16)
Number of Acute Device Success at Time of Index Procedure
Device Success was defined as the achievement of successful delivery and deployment of the study device(s) as intended at the intended target lesion, without balloon rupture or inflation/deflation abnormalities and a successful withdrawal of the study system.
Measured: At time of Index Procedure
Number of Participants With Technical and Procedural Success
Technical Success is defined as successful access and deployment of the device and visual estimate of ≤30% diameter residual stenosis during the index procedure without deployment of a bailout stent.
Procedural Success is defined as attainment of ≤30% residual stenosis in the treatment area by independent core lab analysis without serious adverse events during the index procedure.
Measured: At time of Index Procedure
Number of Participants With Primary Patency at 6, 12, and 24 Months Post Index Procedure
Primary Patency is defined as the absence of target lesion restenosis (defined by core lab adjudication or strict application of PSVR thresholds) and freedom from target lesion revascularization (TLR).
Measured: 6, 12, and 24 months post index procedure
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
Percentage of subjects with Alternative Primary Patency based on alternative definitions of duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) <2.0 and <3.0 at 6, 12, and 24 months post index procedure. DUS PSVR was calculated by dividing the maximum peak systolic velocity (PSV) from the stenosis by the PSV from the nearest segment of normal artery above the site of increase.
Measured: 6, 12, and 24 months post index procedure
Number of Participants With Duplex Ultrasound (DUS) Clinical Patency at 6, 12, and 24 Months Post Index Procedure
DUS Clinical Patency defined as DUS PSVR <2.5 without prior clinically driven target lesion revascularization (TLR).
Measured: 6, 12, and 24 months post index porcedure
Number of Participants With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 6, 12, and 24 Months Post Index Procedure
Measured: 6, 12, and 24 months post index procedure
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
The endpoint summarizes the change in index-limb Rutherford Classification of participants from baseline through 24 months. Data is presented as shift from baseline Rutherford Classification data using the following categories: 1) Improvement, 2) Same, and 3) Worsened.
Measured: 6, 12, and 24 months post index procedure
Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline
Mean change from baseline values. The Ankle Brachial Index (ABI) is defined as a ratio of ankle to brachial (upper arm) artery systolic blood pressure and aims at determining how well the blood is flowing in the legs.
Measured: 6, 12, and 24 months from baseline
Change in Six Minute Walk Test Distance at 6, 12, and 24 Months Compared to Baseline
The data bellow is presented as a Mean change in scores for the Six Minute Walk Test scores at 6, 12, and 24 months compared to baseline.
Measured: 6, 12, and 24 months from baseline
Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 6, 12, and 24 Months Compared to Baseline.
Mean change in EuroQol (EQ-5D) scores at 6, 12, and 24 months compared to baseline. The EurolQol-5D system rates quality of life using five dimensions including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels of ratings, that is, no problems, slight problems, moderate problems, severe problems and extreme problems that can be selected. A visual scale allows participants to report their own perception of their health status. The overall scores range from 0 (worst) to 100 (best). Please note that the data in the table below represent the mean changes in overall scores for each group compared to their baseline data.
Measured: 6, 12, and 24 months
Change in Score on the Short Form Quality of Life Measure (Physical Component) at 6, 12, and 24 Months Compared to Baseline.
Mean change from Baseline on the Short Form (SF-36 v2) Quality of Life Questionnaire at 6, 12, and 24 months. The SF-36 v2 United States (US) is a brief measure of general health status. The physical health measure of the test comprises four scales, that is, physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The scores range between 0 and 100 (with higher scores indicating better health). In the results presented below, a positive Mean represents an increase in the average health score while a negative Mean represents a decrease in the same mean score compared to baseline measure.
Measured: 6, 12, and 24 months
Change in Quality of Life (Mental Component) on the Short-form 36 (SF-36 v2) at 6, 12, and 24 Months Compared to Baseline
Mean change in quality of life (mental component) on Short-form 36 (SF-36 v2) from baseline at 6, 12, and 24 months. The SF-36 v2 United States (US) is a brief measure of general health status. The mental health measure comprises four scales, that is, vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). The scores range from 0 to 100 (with higher scores indicating better health). In the results presented below, a positive Mean represents an increase in the average health score while a negative Mean represents a decrease in the same mean score compared to baseline measure.
Measured: 6, 12, and 24 months from baseline
Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Porcedure
Number of subjects with Freedom from all-cause death, index limb amputation above the ankle and Target Vessel Revascularization (TVR) (VIVA Safety Endpoint)
Measured: 30 days post index procedure
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
Measured: 1, 6, 24, 36, 48, and 60 months post index procedure
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Amputation defined as above the ankle free survival (AFS). PPI = Post index procedure.
Measured: 1, 6, 12, 24, 36, 48, and 60 months post index procedure
Change in Walking Impairment Questionnaire (WIQ) Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline.
The WIQ assesses 3 categories of activities that include 1) walking distance, 2) stair-climbing, and 3) walking speed. Each question requires participants to rate their degree of difficulty with the activity on a scale of 0 (unable) to 4 (no problem). Final scores range from 0% to 100%, with lower percentages indicating higher levels of difficulties with activities.The results below represent the mean differences in total Walking Impairment Questionnaire (WIQ) scores at 6, 12, and 24 months, compared to baseline assessment scores.
Measured: 6, 12, and 24 months post index procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2011 (estimated)
- Study startJul 2011
- Primary completionNov 2013
- Study completionDec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Femoral Artery StenosisStudies of the same condition, open and under way.
- More trials run by C. R. BardThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 532 participants (actual)
Sponsor and investigators
- Lead sponsor
- C. R. Bard
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kenneth Rosenfield, MD, Principal investigator, Massachusetts General HospitalProf. Dierk Scheinert, Principal investigator, University Leipzig
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01412541
- Sponsor's protocol ID
- CL0002-01
- Acronym
- LEVANT 2
- Status last verified
- May 2020
- First submitted
- 5 Aug 2011
- Last updated
- 12 May 2020
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Ma GW, Bernatchez J, Yarranton B, Dueck AD, Rajan DK, Forbes TL, de Mestral C, Kayssi A. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2026 Aug 10;8:CD011319. doi: 10.1002/14651858.CD011319.pub3.
PubMed 42573020Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Pena C, Geraghty P, Lee A, White R, Clair DG. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease. JACC Cardiovasc Interv. 2019 Dec 23;12(24):2515-2524. doi: 10.1016/j.jcin.2019.08.025. Epub 2019 Sep 28.
PubMed 31575518Scheinert D, Schmidt A, Zeller T, Muller-Hulsbeck S, Sixt S, Schroder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease. J Endovasc Ther. 2016 Jun;23(3):409-16. doi: 10.1177/1526602816644592. Epub 2016 Apr 26.
PubMed 27117972Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Muller-Hulsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 9;373(2):145-53. doi: 10.1056/NEJMoa1406235. Epub 2015 Jun 24.
PubMed 26106946
Study at a glance
From the registry record, last updated by the sponsor on 12 May 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Moxy Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries
- ClinicalTrials.gov ID
- NCT01412541
- Acronym / sponsor ID
- LEVANT 2 / CL0002-01
- Conditions
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
- Keywords
- Arms, Experimental, Drug Coated Angioplasty Balloon, Active Comparator, Standard Angioplasty Balloon
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 532 participants (actual)
- Lead sponsor
- C. R. BardIndustry (pharma, biotech, devices)
- Study start
- Jul 2011 (actual)
- Primary completion
- Nov 2013 (actual)
- Study completion
- Dec 2018 (actual)
- First posted
- 9 Aug 2011 (estimated)
- Results
- Posted 29 Mar 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to demonstrate the superior efficacy and non-inferior safety of the Moxy Drug Coated Balloon by direct comparison to standard percutaneous transluminal angioplasty (PTA) catheter for treatment of stenosis of the femoropopliteal arteries.
Detailed description
The Moxy Drug Coated Balloon is indicated for percutaneous transluminal angioplasty of obstructive de novo or non-stented restenotic lesions in native femoropopliteal arteries up to 15 cm in length and ≥4.0 to ≤6.0 mm in diameter. This study will randomize approximately 476 patients who will receive either the Moxy balloon or standard balloon angioplasty at 55 global investigational sites. Subjects will be blinded to treatment until 12 months and will participate in long term follow-up for 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Moxy Drug Coated Balloon | Experimental | Device: Moxy Drug Coated BalloonPaclitaxel coated balloon catheter |
| Standard Uncoated Angioplasty Balloon | Active comparator | Procedure: Standard Uncoated Angioplasty BalloonPTA Catheter |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (19 listed)
- Pregnant or planning on becoming pregnant or men intending to father children;
- Life expectancy of <5 years;
- Patient is currently participating in an investigational drug or other device study or previously enrolled in this study; NOTE: Enrollment in another clinical trial during the follow up period is not allowed.
- History of hemorrhagic stroke within 3 months;
- Previous or planned surgical or interventional procedure within 2 weeks before or within 30 days after the index procedure;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Standard Uncoated Angioplasty BalloonSubjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon | Procedure or surgery | Standard Uncoated Angioplasty Balloon |
| Moxy Drug Coated BalloonSubjects will be randomized 2:1 to the drug coated or standard angioplasty balloon | Device | Moxy Drug Coated Balloon |
Primary outcome
Percentage of Participants With Composite Freedom From All-Cause Peri-Operative (≤30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 12 Months Post Index Procedure
Time frame: 12 months post index procedure
Composite of freedom from all-cause peri-operative (≤30 day) death and freedom at 1 year from the following: index limb amputation (above or below the ankle), index limb re-intervention, and index-limb-related death.
Percentage of Participants With Primary Patency of the Target Lesion at 12 Months Post Index Procedure
Time frame: 12 months post index procedure
Primary Patency is defined as the absence of target lesion restenosis (defined by DUS peak systolic velocity ratio (PSVR) ≥2.5) and freedom from target lesion revascularization (TLR).
16 secondary outcomes
Number of Acute Device Success at Time of Index Procedure
Time frame: At time of Index Procedure
Number of Participants With Technical and Procedural Success
Time frame: At time of Index Procedure
Number of Participants With Primary Patency at 6, 12, and 24 Months Post Index Procedure
Time frame: 6, 12, and 24 months post index procedure
Number of Participants With Alternative Primary Patency at 6, 12, and 24 Months Post Index Procedure
Time frame: 6, 12, and 24 months post index procedure
Number of Participants With Duplex Ultrasound (DUS) Clinical Patency at 6, 12, and 24 Months Post Index Procedure
Time frame: 6, 12, and 24 months post index porcedure
Number of Participants With Freedom From Target Lesion Revascularization (TLR) Clinically-driven at 6, 12, and 24 Months Post Index Procedure
Time frame: 6, 12, and 24 months post index procedure
Improvement in Rutherford Classification Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline
Time frame: 6, 12, and 24 months post index procedure
Change in Resting Ankle Brachial Index (ABI) at 6, 12, and 24 Months Compared to Baseline
Time frame: 6, 12, and 24 months from baseline
Change in Six Minute Walk Test Distance at 6, 12, and 24 Months Compared to Baseline
Time frame: 6, 12, and 24 months from baseline
Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 6, 12, and 24 Months Compared to Baseline.
Time frame: 6, 12, and 24 months
Change in Score on the Short Form Quality of Life Measure (Physical Component) at 6, 12, and 24 Months Compared to Baseline.
Time frame: 6, 12, and 24 months
Change in Quality of Life (Mental Component) on the Short-form 36 (SF-36 v2) at 6, 12, and 24 Months Compared to Baseline
Time frame: 6, 12, and 24 months from baseline
Number of Subjects With Freedom From Death, Index-Limb Amputation, and Target Vessel Revascularization (TVR) at 30 Days Post Index Porcedure
Time frame: 30 days post index procedure
Number of Participants With Composite of Freedom From All-Cause Perioperative (<30 Day) Death and Freedom From the Following at 1,6, 24, 36, 48, and 60 Months: Index Limb Amputation, Index Limb Re-intervention, and Index Limb Related Death
Time frame: 1, 6, 24, 36, 48, and 60 months post index procedure
Number of Participants With All Cause Death, Amputation, Target Vessel Revascularization, Reintervention for Thrombosis, Major and Minor Vascular Complications, and Readmission for Cardiovascular Events at 1, 6, 12, 24, 36, 48, and 60 Months PPI.
Time frame: 1, 6, 12, 24, 36, 48, and 60 months post index procedure
Change in Walking Impairment Questionnaire (WIQ) Scores at 6, 12, and 24 Months Post Index Procedure Compared to Baseline.
Time frame: 6, 12, and 24 months post index procedure
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 May 2020.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42573020Ma GW, Bernatchez J, Yarranton B, Dueck AD, Rajan DK, Forbes TL, de Mestral C, Kayssi A. Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs. Cochrane Database Syst Rev. 2026 Aug 10;8:CD011319. doi: 10.1002/14651858.CD011319.pub3.
- Derived from this study: PubMed 31575518Ouriel K, Adelman MA, Rosenfield K, Scheinert D, Brodmann M, Pena C, Geraghty P, Lee A, White R, Clair DG. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease. JACC Cardiovasc Interv. 2019 Dec 23;12(24):2515-2524. doi: 10.1016/j.jcin.2019.08.025. Epub 2019 Sep 28.
- Derived from this study: PubMed 27117972Scheinert D, Schmidt A, Zeller T, Muller-Hulsbeck S, Sixt S, Schroder H, Weiss N, Ketelsen D, Ricke J, Steiner S, Rosenfield K. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease. J Endovasc Ther. 2016 Jun;23(3):409-16. doi: 10.1177/1526602816644592. Epub 2016 Apr 26.
- Derived from this study: PubMed 26106946Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Muller-Hulsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015 Jul 9;373(2):145-53. doi: 10.1056/NEJMoa1406235. Epub 2015 Jun 24.
Related trials for Femoral Artery Stenosis
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
Active, not recruiting
SELUTION4SFA Trial
Peripheral Arterial Disease, Superficial Femoral Artery Stenosis
Active, not recruiting
First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease
Superficial Femoral Artery Stenosis, Popliteal Artery Stenosis
Recruiting
Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and Pre-Closure
Aortic Stenosis
Not yet recruitingPhase 2/3
A Study Comparing the MAGICTouch™ Sirolimus-coated Balloon With a Paclitaxel-coated Balloon for Treating Severe Narrowing or Blockage in the Femoropopliteal Arteries.
Popliteal Artery Disease, Superficial Femoral Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kenneth Rosenfield, MD principal investigator
Massachusetts General Hospital
Prof. Dierk Scheinert principal investigator
University Leipzig
54 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Standard Uncoated Angioplasty Balloon and Moxy Drug Coated Balloon in people with Femoral Artery Stenosis and Popliteal Artery Stenosis, run by C. R. Bard at 54 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 May 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 54 sites in United States, Germany, Austria, Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 29 Mar 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Composite Freedom From All-Cause Peri-Operative (≤30 Day) Death and Freedom From Index Limb Amputation, Index Limb Re-Intervention, and Index-Limb-Related Death at 12 Months Post Index Procedure (time frame: 12 months post index procedure). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01412541, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2020.